Dr. Erban is an internationally known expert in breast cancer diagnosis and treatment. He is the Clinical Director and Associate Director for Clinical Research at Tufts University School of Medicine. He is Associate Editor of the American Journal of Clinical Oncology, past President of the Massachusetts Society of Clinical Oncology and has been a member of both the Eastern Cooperative Oncology Group Breast Cancer Committee and the NCCN Clinical Breast Cancer Guidelines Committee.
John K. Erban, M.D.
Dr. Long is a business executive with over 20 years of biotechnology industry experience in strategic planning, business development and R&D management. Previously, she was vice president of business development at Genzyme Corporation where she led business strategy and partnering activities for the Biosurgery Division. She is keenly interested in mentoring young scientists and engineer entrepreneurs and is a judge and mentor for a number of business plan competitions, including MassChallenge, MALSI, and the Tufts 100K. She is an IRB member at the New England Baptist Hospital. Dr. Long has a Ph.D. in microbiology from the University of Cape Town, South Africa and completed a post-doctoral fellowship in molecular biology at the Massachusetts Institute of Technology.
Susan Long, Ph.D.
Dr. Marshak-Rothstein is a Professor of Medicine at the University of Massachusetts Medical School. She is world renowned for her work in immune cell activation, longevity and function. She served as Director of the Hybridoma Laboratory at Boston University, holds several monoclonal antibody-based patents and is an expert on the preparation of monoclonal antibodies. Dr. Marshak-Rothstein is on the Editorial Board of the Annual Review of Immunology and was the recipient of the Lupus Research Institute Distinguished Innovator Award.
Ann Marshak-Rothstein, Ph.D.
Dr. Romagnoli is a co-founder of Adecto Pharmaceuticals. She is an expert in the pathophysiology of cancer, including mechanisms of oncogenesis and chemoresistance and the identification of new targets for treatment. As a Postdoctoral Research Associate at Tufts University School of Medicine, she identified the role of ADAM8 in breast cancer and validated the efficacy of an antibody-based approach in treatment. Dr. Romagnoli holds a Ph.D. in Hematology/Oncology from the Comprehensive Cancer Center of Nantes, France.